Deng IBD

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/60

encourage image

There's no tags or description

Looks like no tags are added yet.

61 Terms

1
New cards

What is IBD

A group of inflammatory conditions of the GI tract, mainly in the colon and small intestine

2
New cards

2 types of IBD

UC and CD

3
New cards

Shared features of UC and CD

Uknown etiology

Inflammation related

More common in western societies

Low frequency among non-whites

Both sexes affected equally

Usually affect people before the age of 40

Tend to occur in the same families

4
New cards

Different features of UC and CD

Incidence of UC is static whereas CD is increasing

Only the colon is affected in UC but CD can affect the entire GI tract

UC is superficial and affects Continuous areas

CD affects deep tissue with skip lesions

With CD fistula and fissure formation is possible

5
New cards

Idiopathic disease

Means the cause is unknown

6
New cards

Treatment target

Symptoms

7
New cards

Risk factors for IBD

Genetics, infection, immunological, environmental

8
New cards

Defenses of the Intestine

Mucus

Peyer’s patch and M cells

Paneth Cells

Macrophages, granulocytes, DC, T and B cells

Microflora

Epithelial Cells

9
New cards

Role of macrophages in IBD

When macrophages have a NOD2 defect they can become infected. This leads to chronic T cell stimulation by the infected macrophages resulting in inflammation.

10
New cards

NOD 2

Nucleotide binding Oligomerization domain containing 2

Recognizes molecules containing specific structures that are found in bacteria.

Expressed in macrophages, APC, epithelial cells, endothelial cells and T cells

11
New cards

Defective Epithelial Cell Response in IBD

In IBD the structure of GI epithelium changes, leading to gaps between cells. This leads to a loss in barrier function and increased exposure to the mucosal microflora. This leads to increased effector response and inflammation.

12
New cards

Normal epithelial Resposnes

Normal epithelium is tightly packed cells. These cells can be activated to produce defensins which protect against the microflora as well as chemokines.

13
New cards

Defects in antigen presenting cells in IBD

NOD2 defect can lead to the inappropriate activation of APCs. This causes disruption of the homeostatic balance of effector and regulatory cells

<p>NOD2 defect can lead to the inappropriate activation of APCs. This causes disruption of the homeostatic balance of effector and regulatory cells </p>
14
New cards

Which cytokines are pro-inflammatory

IL-1,2,8,12

TNFa and IFN

15
New cards

Which cytokines are anti-inflammatory

IL-10

Regulatory

Suppresses immunoresponse

16
New cards

Tumor Necrosis Factor Alpha

The central cytokine for IBD. The primary target for existing therapies.

17
New cards

Effects of TNF-a activation

Increases lymphocyte recruitment

Increases endothelial activation (adhesion molecules, permeability)

Increases neutrophil recruitment

18
New cards

TNF-a effect on intestinal epithelium

Increases keratinocyte growth factor, epidermal growth factor, MHC class 1 + 2, matrix metalloproteinase

19
New cards

TNF-a effect on endothelium

Increases adhesion molecules, selecting, VCAM, ICAM

20
New cards

TNF-a effect on macrophages

Increase IL-12, granulocyte macrophage colony stimulating factor, IL-6

21
New cards

TNF-a effect on neutrophils

Increases recruitment, activation, and delays apoptosis

22
New cards

TNF-a effect on lymphocytes

Increases recruitment, activation, and delays apoptosis

23
New cards

Intracellular adhesion molecule-1

Normally expressed in high levels on endothelial cells and leukocyte.

Induced by IL-1 and TNFa

A ligand for LFA-1, receptor found on leukocytes

When activated, leukocytes bind to endothelial cells via ICAM/LFA and then transmigrated into tissue

24
New cards

Objectives for IBD treatment include

Alleviate the disease and symptoms

Maintain remission

25
New cards

Overview of IBD treatment

Pharmacological - anti-inflammatory and immunosuppressive agents

Surgery

Antioxidants

Bacterial recolonization (probiotics)

Helminthic therapy

Herbal/Dietary modifications

Antibiotics

26
New cards

Groups of pharmacological therapies

Anti-inflammatory drugs: NSAID, corticosteroids, adrenocorticotropic hormone

Immunosuppressive therapies: chemical and biological

Combination therapies of both, usually want to pick drugs with different MOAs

27
New cards

Aminosalicylates

Non-Steroidal Anti-Inflammatory drug

Active ingredient is 5-aminosalicylic acid (5-ASA)

Has poor intestine absorption so it provides topical relief within the intestine

28
New cards

Formulations of 5-ASA

Mesalamine - 5-ASA

Sulfasalazine, Balazide, Olsalazine - Release 5-ASA by resident bacteria in terminal ileum and colon

29
New cards

Amino salicylates mechanism of action

They inhibit LOX and COX in the Arachidonic acid cascade preventing the production of leukotrienes and prostaglandins that normally lead to inflammation

30
New cards

Corticosteroid MOA transactivation

  • Corticosteroids diffuse across the cell membrane due to their lipid solubility.

  • Bind to cytoplasmic glucocorticoid receptors (GR).

  • The corticosteroid-GR complex moves into the nucleus.

  • Complex binds to glucocorticoid response elements (GREs) on DNA.

  • Recruits coactivator proteins (GRIP-1, CBP, pCAF, and HAT).

  • HAT adds acetyl groups to histones, loosening DNA packaging.

  • Increases transcription of anti-inflammatory genes.

  • Produces anti-inflammatory proteins (Annexin-1, SLPI, MKP-1, IκB-α, GILZ).

  • These proteins suppress inflammatory pathways, reducing inflammation.


31
New cards

Corticosteroids MOA trans repression

  • Inflammatory stimuli (e.g., IL-1β and TNF-α) activate the IKK-2 pathway.

  • IKK-2 activates NF-κB (p65/p50), allowing it to move into the nucleus.

  • NF-κB recruits coactivators (CBP, pCAF, and HAT), promoting histone acetylation.

  • Histone acetylation increases transcription of pro-inflammatory genes.

  • Corticosteroids diffuse across the cell membrane and bind cytoplasmic glucocorticoid receptors (GR).

  • The corticosteroid-GR complex enters the nucleus and interacts with NF-κB.

  • GR recruits HDAC2 (histone deacetylase 2), which removes acetyl groups from histones.

  • Deacetylation tightens DNA packaging, reducing transcription of pro-inflammatory genes.

  • Production of inflammatory cytokines, chemokines, adhesion molecules, and inflammatory enzymes decreases.


32
New cards

Corticosteroid trans activation of anti-inflammatory molecules

Increased production of:

Annexis-1

SLPI (secretory Leukoprotease inhibitor)

MKP-1 (mitogen-activated kinase phosphatase-1)

IkBa (inhibitor of NF-kB)

GILZ (glucocorticoid-induced leucine zipper protein)

33
New cards

Corticosteroid trans repression of inflammatory molecules

Decrease production of:

Cytokines

Chemokines

Adhesion molecules

Inflammatory enzymes

Inflammatory receptors

Inflammatory proteins

34
New cards

Corticosteroid cis-repression

This is what leads to negative side effects

Decreases production of

POMC (proopiomelanocortin)

CRF-1 (corticotrophin releasing factor)

Osteocalcin

Keratin

35
New cards

Cortisol

The bodies natural glucocorticoid that produces anti-inflammatory and immunosuppressive effects. Has same MOA.

36
New cards

HPA Axis (hypothalamic-pituitary-adrenal)

  1. The hypothalamus releases corticotropic releasing hormone (CRH)

  2. In response the anterior pituitary gland releases ACTH

  3. ACTH stimulate the adrenal cortex to increase release of cortisol


37
New cards

Examples of purine analogs

Immunosuppressives

Azathioprine and 6-mercaptopurine

38
New cards

MOA of purine analogs

  • Azathioprine is converted into 6-mercaptopurine (6-MP).

  • 6-MP acts as a purine analog.

  • Interferes with normal purine synthesis via ribose phosphate

  • Decreases production of purine nucleotides (ATP and GTP).

  • Reduces DNA and RNA synthesis.

  • Inhibits proliferation of cells, especially leukocytes.

  • Produces an immunosuppressive effect.


39
New cards

Cyclosporine MOA

-

40
New cards

Chemical immunosuppressives

Purine analogs

Cyclosporine - calcineurin inhibitor

Methotrexate

MMP inhibitors

TNFa antagonists

41
New cards

Cyclosporine MOA

  • Cyclosporine enters the T cell.

  • Binds to a protein called cyclophilin.

  • Forms a cyclosporine-cyclophilin complex.

  • The complex inhibits calcineurin.

  • Calcineurin can no longer activate NFATc.

  • Decreases IL-2 gene expression.

  • Decreases T-cell growth, differentiation, and activation.

  • Produces immunosuppression.


42
New cards

Methotrexate MOA

  • Methotrexate produces effects involving folate and adenosine pathways.

  • Suppresses T-cell activation.

  • Decreases ICAM-1 expression.

  • Promotes apoptosis of activated T cells.

  • Reduces immune activity and inflammation.


43
New cards

MMP MOA

  • MMPs are enzymes that require zinc for their activity.

  • MMP inhibitors bind/chelate zinc at the MMP catalytic site.

  • Zinc is removed from the catalytic site.

  • MMP activity is inhibited.

  • Conversion of membrane-bound TNF-α into free TNF-α is reduced.

  • Decreases this source of soluble TNF-α and inflammatory signaling



44
New cards

Which drugs are TNFa antagonists

Infliximab

Adalimumab

Etanercept

Certolizumab

45
New cards

New generation of TNFa antagonist: Golimumab

Fourth generation of TNFa antagonist

Fully humanized mAb with high affinity for TNFa

Better safety profile

Approved in 2014 for UC

46
New cards

MOA of integrin antagonist: Natalizumab

  • Natalizumab binds to α4 integrin on leukocytes.

  • Blocks α4 integrin interactions with VCAM-1 and MAdCAM-1.

  • Prevents leukocytes from adhering properly to endothelial cells.

  • Decreases leukocyte migration into intestinal tissue.

  • Reduces intestinal inflammation.


47
New cards

Natalizumab (Tysabri)

A humanized mAb

Targeting to a4 integrin complex with B1 or B7 subunit

CDR grafted from murine Ab

48
New cards

Vedolizumab MOA

Selectively prevent leukocyte migration into the GI tract.

  1. Vedolizumab binds specifically to α4β7 integrin.

  2. Blocks the interaction between α4β7 integrin and MAdCAM-1.

  3. Prevents leukocytes from migrating into GI tissue.

  4. Reduces intestinal inflammation.


49
New cards

Vedolizumab (Entyvio)

New generation of integrin antagonist

Specific a4B7

Approved in 2014 for both CD and UC

50
New cards

Ustekinumab MOA

  • Binds the common p40 subunit shared by IL-12 and IL-23.

  • Prevents IL-12 and IL-23 from carrying out their inflammatory signaling.

  • Decreases cytokine-mediated immune activation.

  • Reduces inflammation.


Approved for both CD and UC. Positive results in treating CD patients who failed anti TNFa therapy

51
New cards

Risankizumab

  • Binds the IL-23A subunit.

  • Prevents IL-23 from carrying out its inflammatory signaling.

  • Decreases IL-23-mediated immune activity.

  • Reduces inflammation.


Approved for Crohn’s

52
New cards

Ozanimod

Is a sphingosine-1-phosphate receptor modulator (agonist)

approved for UC

S1P is expressed on T and NK cells

By binding to S1P1 it reduces the number of T cells in circulation from lymph nodes

53
New cards

Ozanimod MOA

  • Ozanimod binds to S1P receptors (S1P1 and S1P5).

  • Binding to S1P1 causes receptor internalization.

  • Prevents normal lymphocyte movement from lymph nodes into circulation.

  • Sequesters lymphocytes in peripheral lymphoid organs.

  • Decreases the number of circulating lymphocytes available to enter inflamed intestinal tissue.

  • Reduces intestinal inflammation.


54
New cards

JAK inhibitors - small molecules

Upadacitinib and Tofacitinib

55
New cards

JAKis MOA

  • Tofacitinib or upadacitinib inhibits JAK activity.

  • Prevents normal JAK-mediated activation of STAT.

  • Decreases intracellular inflammatory signaling.

  • Reduces expression of immune and inflammation-related responses.

  • Produces immunosuppressive and anti-inflammatory effects.


56
New cards

Antioxidants

  • A metabolic defect leads to the accumulation of hydroxyl and other radicals beneath the cell membrane.

  • These radicals damage cellular membranes.

  • Membrane destruction contributes to ulcerative colitis.

  • Antioxidants may help neutralize these damaging radicals.

  • This may protect cell membranes from oxidative damage.


57
New cards

What is a probiotic

Live microorganism which when administered in adequate amount confer a health benefit on the host. Examples include certain yeasts, lactic acid bacteria, bifidobacteria, bacilli

58
New cards

What are prebiotics

A selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the GI microflora that confers benefits upon host well-being and health. Examples: inulin, oligofructose

59
New cards

Probiotics MOA

  • IBD may be associated with dysbiosis (an imbalance of intestinal microbial flora).

  • An imbalance may allow pathogens to invade the intestinal wall.

  • Probiotics introduce beneficial microorganisms.

  • Improve the balance of intestinal microflora.

  • Inhibit pathogens and toxin-producing bacteria.

  • May improve IBD.


60
New cards

Prebiotics MOA

  • Prebiotics provide substrates that are selectively fermented by intestinal microorganisms.

  • Change the composition and/or activity of intestinal microflora.

  • Promote beneficial effects on intestinal health.


61
New cards

Helminthic Therapy MOA

  • Absence of helminths (intestinal worms).

  • May contribute to abnormal intestinal immune regulation.

  • Leads to abnormal intestinal immune responses.

  • May contribute to bowel inflammation.

  • Helminthic therapy introduces controlled exposure to helminths.

  • May help regulate intestinal immune responses and reduce inflammation.


Supporting evidence: BD is much less in developing world where the parasite is common. Mutualism vs parasitism. Clinical data showed efficacy in patients with the therapy